Skip to main content

Table 1 Included cancer drugs in the analysis and number of reports per jurisdiction

From: Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports

Active ingredient /generic name

Brand name

Indication

ZIN

NICE

CADTH

PBAC/MSAC

Dabrafenib and trametinib

Tafinlar and mekenist

Melanoma

1

1

1

1

Ipilimumab and nivolumab

Yervoy and Opdivo

Renal cell carcinoma

1

1

1

1

Venetoclax and retuximab

Venclyxto and generic

Chronic lymphocytic leukaemia

1

1

1

1

Durvalumab

Imfinzi

Non-small cell lung cancer

1

1

1

1

Abemaciclib

Verzenios

Breast cancer

1

2

1

1

Axicabtagene ciloleucel

Yeskarta

Large B-cell lymphoma

1

1

1

1

Tisagenlecleucel

Kymriah

Large B-cell lymphoma/Acute lymphocytic leukaemia

2

2

1

2

Dinutuximab beta

Qarziba

Neuroblastoma

1

1

1

0

Osimertinib

Tagrisso

Non-small cell lung cancer

1

1

1

1

Atezolizumab

Tecentriq

Non-small cell lung cancer

1

1

1

1

Ribociclib

Kisqali

Breast cancer

1

1

1

1

Daratumumab

Darzalex

Myeloma

1

1

1

1

Cetuximab

Erbitux

Colorectal cancer

1

1

1

1

Ibrutinib

Imbruvica

Lymphocytic leukaemia

1

1

2

1

Palbociclib

Ibrance

Breast cancer

1

2

2

1

  1. ZIN Zorginstituut Nederland, NICE National Institute for Health and Care Excellence, CADTH Canadian Agency for Drugs and Technologies in Health, PBAC Pharmaceutical Benefit scheme and medical services Advisory, MSAC Medical Services Advisory Committee